About US
Contact us
-
Lawmakers demand Purdue Pharma's list of suspect OxyContin prescribersLawmakers demand Purdue Pharma's list of suspect OxyContin prescribers Now thatPurdue Pharmahas acknowledged news reports that it compiled a list of 1,800 doctors suspected of churning outOxyContin2013/8/14
-
Russia's Pharmstandard still weighing OTC unit sale, exec saysIn late June, Russia's Pharmstandard was reportedly considering a sale of itsOTCbusiness. A couple of weeks later, the company said it would spin the unit off instead. But the fate of that business is2013/8/13
-
Roche chief's comments about deal discipline push shares upHere's the latest example of parsing a pharma CEO's statements about M&A: After Roche ($RHHBY) chiefSeverin Schwansaid over the weekend that deals have to be "worth it financially," Notenstein ana2013/8/13
-
European Commission grants J&J, Celgene blood cancer approvalsTheEuropean Commissionwas good to blood cancer drugmakers this week, grantingmultiple myelomaapprovals for Johnson & Johnson's ($JNJ)Velcadeand Celgene's ($CELG)Imnovid. While Velcade was already2013/8/12
-
Sun has terrific quarter, except for that Pfizer thingSales were up, as were profits when settlement payment factored out India'sSun Pharmaceutical Industrieshad a really good quarter, except for that one thing with Pfizer ($PFE). Its sales in the U.S.2013/8/12
-
Pharma professionals feeling angst, but see a few rays of hopeMore than half of pharma pros expect to lose their jobs in the next year Any survey, even when looking ahead, can't help but reflect what is going on in the here-and-now. And so with the patent cliff2013/8/9
-
Disgraced researcher blames GSK pressure for Chinese data lapsesGlaxoSmithKline ($GSK) wasn't the only Big Pharma company to set up R&D operations inChina. But a feature inBloombergtoday highlights GSK's unusual decision to give its research division there the2013/8/9
-
GlaxoSmithKline CEO's reform-minded rep under fire in China probeWas GlaxoSmithKline ($GSK) CEOAndrew Wittylooking in the wrong direction when he pledged to clean up his company's act? As theWall Street Journalreports, Witty has focused heavily on reforming the com2013/8/7
-
New data for Bayer, Regeneron drug Eylea may help it gain ground from LucentisBayer's eye drugEyleahas already enjoyed a wealth of success since its approval, and now it looks to be in for much more. The company has announced positive late-stage study data that could put the dr2013/8/7
-
2014’ PHEXCOM Events Schedule2014’ PHEXCOM Events Schedule Dear VIP members： For the sake of providing better service to satisfy your demand, we prepared the “ 2014 PHEXCOM Events schedule”. Please mark “√”on “□” which you2013/8/6